Welcome to our dedicated page for RenovoRx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.
RenovoRx, Inc. (RNXT) is a medical device and biopharmaceutical company based in Silicon Valley, California. The company focuses on developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents to specific locations in the peripheral vascular system. With FDA clearance for their flagship product, RenovoCath™ RC120, RenovoRx is introducing this cutting-edge technology to the clinical market.
RenovoRx's proprietary platform, Trans-Arterial Micro-Perfusion (TAMP), aims to revolutionize cancer treatment by ensuring precise therapeutic delivery directly to the tumor site. This targeted approach is designed to reduce the toxicities commonly associated with systemic intravenous therapy, potentially improving therapeutic outcomes for cancer patients.
The company is driven by a highly motivated team with extensive experience in the medical field and supported by a robust medical advisory board and a distinguished board of directors. RenovoRx's commitment to innovation and patient care has positioned it as a leader in the area of targeted therapeutic delivery.
For more information or inquiries, please contact RenovoRx at info@renovorx.com.
RenovoRx has raised $17.2 million in gross proceeds since early 2024, enabling the advancement of its pivotal Phase III TIGeR-PaC clinical trial for Locally Advanced Pancreatic Cancer (LAPC) and the expansion of its drug-delivery platform into additional cancer indications. The company, led by CEO Shaun Bagai, aims to improve patient outcomes with its precision oncology therapies. Recent promotions within the management team and publications supporting the Trans-Arterial Micro-Perfusion (TAMP) platform demonstrate progress. A second interim analysis for the TIGeR-PaC trial is expected by late 2024, following the completion of the first interim analysis in March 2023.
RenovoRx has announced the publication of pre-clinical studies demonstrating the efficacy of its Trans-Arterial Micro-Perfusion (TAMP) therapy platform.
The data, published in the Journal of Vascular Interventional Radiology, reveals a 100-fold increase in local tissue concentration of chemotherapy when using TAMP compared to conventional intravenous delivery.
TAMP aims to improve the safety and efficacy of oncology therapies by delivering drugs directly to solid tumors, potentially reducing systemic toxicity and widening the therapeutic window.
The studies were co-authored by experts from the Oregon Health and Science University, University of Pittsburgh Hillman Cancer Center, and RenovoRx.
The platform could address unmet needs in localized drug delivery, pending validation from ongoing Phase III clinical trials.
RenovoRx, a clinical-stage biopharmaceutical company (Nasdaq: RNXT), will take part in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024. CEO Shaun Bagai will discuss the company's recent milestones, including raising $17.2 million through private placements. This funding will support RenovoRx's Phase III TIGeR-PaC clinical trial for its lead product, RenovoGem, aimed at treating locally advanced pancreatic cancer. The TIGeR-PaC's second interim analysis is anticipated by late 2024. The event will be moderated by Scott Henry, Managing Director at A.G.P.
RenovoRx, Inc. (RNXT) CEO Shaun R. Bagai will present at the Aegis Capital Virtual Conference on May 9, 2024. The company recently completed private placements raising $17.2 million. This funding will support the Phase III TIGeR-PaC clinical trial for RenovoGem™ in locally advanced pancreatic cancer. The second interim analysis is expected in late 2024.
FAQ
What is the current stock price of RenovoRx (RNXT)?
What is the market cap of RenovoRx (RNXT)?
What does RenovoRx, Inc. specialize in?
What is the RenovoCath™ RC120?
What is the Trans-Arterial Micro-Perfusion (TAMP) platform?
Where is RenovoRx headquartered?
Who backs RenovoRx's initiatives?
What is the primary goal of RenovoRx's therapies?
How can I contact RenovoRx for more information?
What makes RenovoRx's technology unique?
Is RenovoRx currently in clinical stages?
What recent achievements has RenovoRx made?
